Cite
MLA Citation
Uwe Platzbecker et al.. “Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.” Lancet oncology, vol. 19, no. 12, 2018, pp. 1668–1679. http://access.bl.uk/ark:/81055/vdc_100073670405.0x00001d